NorthStrive Biosciences, a wholly owned subsidiary of PMGC Holdings Inc., filed a new U.S. patent application for its EL-22 myostatin-engineered probiotic technology targeting muscle preservation in human pharmaceutical applications.
Key takeaways
NorthStrive Biosciences filed U.S. Patent Application No. 19/655,160 for EL-22 in human muscle loss treatments.
EL-22 targets sarcopenia, muscle disuse atrophy, and neurological disorders with specific dosing and formulations.
Expands IP strategy from prior muscle preservation applications into human pharmaceuticals.
EL-22 supports muscle preservation during weight loss treatments like GLP-1 receptor agonists.
Strengthens NorthStrive's portfolio focused on muscle health therapeutics.